公开(公告)号：EP1836158A1

公开(公告)日：2007-09-26

申请号：EP05818685.9

申请日：2005-12-17

申请人： Sanofi-Aventis Deutschland GmbH

发明人： KNIEPS, Stephanie ,  DEDIO, Juergen ,  HEITSCH, Holger ,  CZECHTIZKY, Werngard ,  GRUENEBERG, Sven ,  SHIMSHOCK, Stephen ,  KOSLEY, Raymond, W. ,  LANTER, Carolina ,  LI, Hui ,  SHER, Rosy ,  WEICHSEL, Aleksandra

IPC分类号： C07C235/66 ,  C07D319/20 ,  C07D261/08 ,  C07D271/12 ,  C07D215/14 ,  C07D249/18 ,  C07D277/64 ,  C07D231/12 ,  C07D207/32 ,  C07D249/08 ,  C07D263/32 ,  C07D213/30 ,  C07D249/06 ,  C07D213/68 ,  C07D213/69

CPC分类号： C07D213/68 ,  C07D207/325 ,  C07D213/30 ,  C07D213/65 ,  C07D213/69 ,  C07D215/14 ,  C07D217/26 ,  C07D231/12 ,  C07D233/64 ,  C07D249/06 ,  C07D249/08 ,  C07D249/18 ,  C07D261/08 ,  C07D263/32 ,  C07D271/12 ,  C07D277/24 ,  C07D277/64 ,  C07D307/42 ,  C07D317/54 ,  C07D319/20 ,  C07D333/56 ,  C07D333/70 ,  C07D409/12 ,  C07D417/12 ,  C07D495/04

摘要： The invention relates to compounds of the formula (I) in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases such as inflammatory diseases.

公开(公告)号：EP2041072A1

公开(公告)日：2009-04-01

申请号：EP07726150.1

申请日：2007-06-25

申请人： Sanofi-Aventis

发明人： HACHTEL, Stephanie ,  DEDIO, Jürgen ,  PERNERSTORFER, Josef ,  SHIMSHOCK, Stephen ,  LANTER, Carolina ,  KOSLEY, Raymond, W.

IPC分类号： C07C235/66 ,  C07D213/65 ,  C07D285/14 ,  A61K31/166 ,  A61P29/00

CPC分类号： C07C235/66 ,  C07C2602/08 ,  C07C2602/10 ,  C07D213/30 ,  C07D277/64 ,  C07D333/54

摘要： The invention relates to compounds of the formula (I) in which R1, R2, A, B, X and Y have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

公开(公告)号：EP2040688A1

公开(公告)日：2009-04-01

申请号：EP07785841.3

申请日：2007-06-25

申请人： Sanofi-Aventis

发明人： HACHTEL, Stephanie ,  DEDIO, Juergen ,  DEFOSSA, Elisabeth ,  GRUENEBERG, Sven ,  HEITSCH, Holger ,  BOCK, William ,  CHEN, Charlie ,  KOSLEY, Raymond ,  KUNG, Chung-Yi ,  PATEK, Marcel ,  SHER, Rosy ,  SHIMSHOCK, Stephen ,  WEICHSEL, Aleksandra

IPC分类号： A61K31/166 ,  A61P29/00 ,  C07C235/66 ,  C07D215/24 ,  C07D333/64 ,  C07D213/30

CPC分类号： C07D333/16 ,  C07C233/83 ,  C07C235/66 ,  C07C237/48 ,  C07C311/29 ,  C07C2601/04 ,  C07C2601/10 ,  C07C2601/14 ,  C07C2602/08 ,  C07D213/65 ,  C07D215/26 ,  C07D233/60 ,  C07D295/088 ,  C07D307/24 ,  C07D333/64

摘要： The invention relates to compounds of the formula (I), in which R1, R2, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

公开(公告)号：EP2040690A1

公开(公告)日：2009-04-01

申请号：EP07764812.9

申请日：2007-06-25

申请人： Sanofi-Aventis

发明人： HACHTEL, Stephanie ,  DEDIO, Juergen ,  SHIMSHOCK, Stephen ,  LANTER, Carolina

IPC分类号： A61K31/195 ,  A61K31/351 ,  A61K31/381 ,  A61K31/382 ,  A61K31/428 ,  A61K31/4436 ,  C07C235/66 ,  C07D277/64 ,  C07D309/14 ,  C07D335/02 ,  C07D407/12 ,  C07D409/12

CPC分类号： C07D277/64 ,  C07C235/66 ,  C07C2601/10 ,  C07D307/24 ,  C07D309/14 ,  C07D335/02 ,  C07D409/12 ,  C07D417/12

摘要： The invention relates to compounds of the formula I in which R1, R2, X, A, B and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

公开(公告)号：EP2041073A1

公开(公告)日：2009-04-01

申请号：EP07764813.7

申请日：2007-06-25

申请人： Sanofi-Aventis

发明人： HACHTEL, Stephanie ,  DEDIO, Juergen ,  PERNERSTORFER, Josef ,  SHIMSHOCK, Stephen ,  LANTER, Carolina

IPC分类号： C07C235/66 ,  C07D333/32 ,  A61K31/166 ,  A61P29/00

CPC分类号： C07D333/16 ,  C07C235/66 ,  C07C2601/14 ,  C07C2602/10 ,  C07D333/54

摘要： The invention relates to compounds of the formula (I), in which R1, R2, A, B, X and Y have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.